Trial Profile
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Tirzepatide (Primary) ; Dulaglutide
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 05 Oct 2021 Results (n=259) of post-hoc analysis assessing plasma metabolome changes mediated by tirzepatide, published in the Journal of Clinical Endocrinology and Metabolism.
- 25 Nov 2020 Results of post-hoc analysis assessing effects of tirzepatide on biomarkers associated with pancreatic beta-cell function and insulin sensitivity published in the Journal of Clinical Endocrinology and Metabolism
- 17 Nov 2020 Results of post hoc analysis assessing effect of Tirzepatide in cardiovascular risk protein biomarkers in patients with type 2 diabetes, presented at the American Heart Association Scientific Sessions 2020